Jun 11, 2020 / 07:00PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. Good afternoon, everyone. I'm Paul Choi, the SMid cap biotechnology analyst here at Goldman Sachs. And we'll continue with our next session, which is Kiniksa Pharmaceuticals. I'm very pleased to host from the management team here today, Chairman and CEO, Sanj Patel. We're also joined by the Chief Medical Officer, John Paolini, and as well as Qasim Rizvi, who is the Chief Commercial Officer. I believe we also have Eben Tessari on the line as well here.
As with past sessions, I'll kick it off with some intro comments and then turn it over to Sanj for some opening remarks. We'll proceed then with the Q&A portion of the session. And if along the way, any clients who are listening have questions, please feel free to submit them via the Goldman Sachs research portal and time permitting at the end, we'll read them out loud. Alternatively, investors can send questions to me directly as well.
And so with that, we'll kick off the session. And Sanj, if you want to kick it off here with any opening remarks?
Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 12, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers